Hsu Hung-Te, Lo Yi-Ching, Huang Yan-Ming, Tseng Yu-Ting, Wu Sheng-Nan
Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung City, 80708, Taiwan.
Department of Anesthesia, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung City, 80145, Taiwan.
BMC Neurosci. 2017 Jan 3;18(1):6. doi: 10.1186/s12868-016-0320-5.
Sugammadex (SGX) is a modified γ-cyclodextrin used for reversal of steroidal neuromuscular blocking agents during general anesthesia. Despite its application in clinical use, whether SGX treatment exerts any effects on membrane ion currents in neurons remains largely unclear. In this study, effects of SGX treatment on ion currents, particularly on delayed-rectifier K current [I ], were extensively investigated in differentiated NSC-34 neuronal cells.
After cells were exposed to SGX (30 μM), there was a reduction in the amplitude of I followed by an apparent slowing in current activation in response to membrane depolarization. The challenge of cells with SGX produced a depolarized shift by 15 mV in the activation curve of I accompanied by increased gating charge of this current. However, the inactivation curve of I remained unchanged following SGX treatment, as compared with that in untreated cells. According to a minimal reaction scheme, the lengthening of activation time constant of I caused by cell treatment with different SGX concentrations was quantitatively estimated with a dissociation constant of 17.5 μM, a value that is clinically achievable. Accumulative slowing in I activation elicited by repetitive stimuli was enhanced in SGX-treated cells. SGX treatment did not alter the amplitude of voltage-gated Na currents. In SGX-treated cells, dexamethasone (30 μM), a synthetic glucocorticoid, produced little or no effect on L-type Ca currents, although it effectively suppressed the amplitude of this current in untreated cells.
The treatment of SGX may influence the amplitude and gating of I and its actions could potentially contribute to functional activities of motor neurons if similar results were found in vivo.
舒更葡糖钠(SGX)是一种修饰的γ-环糊精,用于全身麻醉期间甾体类神经肌肉阻滞剂的逆转。尽管其已应用于临床,但SGX治疗是否对神经元膜离子电流产生任何影响仍不清楚。在本研究中,我们在分化的NSC-34神经元细胞中广泛研究了SGX治疗对离子电流的影响,特别是对延迟整流钾电流[I]的影响。
细胞暴露于SGX(30μM)后,I的幅度降低,随后响应膜去极化的电流激活明显减慢。用SGX刺激细胞导致I的激活曲线发生15mV的去极化偏移,并伴有该电流门控电荷增加。然而,与未处理的细胞相比,SGX处理后I的失活曲线保持不变。根据一个最小反应方案,用17.5μM的解离常数定量估计了不同SGX浓度处理细胞引起的I激活时间常数的延长,该值在临床上是可以达到的。在SGX处理的细胞中,重复刺激引起的I激活的累积减慢增强。SGX处理未改变电压门控钠电流的幅度。在SGX处理的细胞中,合成糖皮质激素地塞米松(30μM)对L型钙电流几乎没有影响,尽管它能有效抑制未处理细胞中该电流的幅度。
SGX治疗可能影响I的幅度和门控,如果在体内发现类似结果,其作用可能有助于运动神经元的功能活动。